A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid Leukemia

2023-507677-18-00 Protocol TERN701-1012 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 17 May 2024 · Status Ongoing, recruiting · 4 EU/EEA countries · 24 sites · Protocol TERN701-1012

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 219
Countries 4
Sites 24

Chronic Myeloid Leukemia

Key facts

Sponsor
Terns Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
17 May 2024 → ongoing
Decision date (initial)
2024-04-29
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2023-507677-18-00
ClinicalTrials.gov
NCT06163430

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic Myeloid Leukemia

VersionLevelCodeTermSystem organ class
21.0 LLT 10009700 CML 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Terns Inc.

Sponsor organisation
Terns Inc.
Address
1065 East Hillsdale Boulevard Suite 100
City
Foster City
Postcode
94404-1688
Country
United States

Scientific contact point

Organisation
Terns Inc.
Contact name
Leanne Holes

Public contact point

Organisation
Terns Inc.
Contact name
Study Director

Locations

4 EU/EEA countries · 24 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 26 6
Germany Ongoing, recruiting 25 7
Italy Ongoing, recruiting 12 3
Spain Ongoing, recruiting 40 8
Rest of world
New Zealand, United States, Australia, India, United Kingdom, Korea, Republic of, Canada
116

Investigational sites

France

6 sites · Ongoing, recruiting
Centre Leon Berard
Medical Oncology, 28 Rue Laennec, 69008, Lyon
Institut Bergonie
Hematology Department, 229 Cours De L Argonne, 33000, Bordeaux
Hopital Saint Louis
Division of Hematology and Immunology Adult Hematology Department and Apheresis Unit, 1 Avenue Claude Vellefaux, 75010, Paris
Hospital Hotel Dieu
Clinical Hematology, 1 Place Alexis Ricordeau, 44000, Nantes
Centre Hospitalier Lyon Sud
Hematology, 165 Chemin Du Grand Revoyet, 69310, Pierre-Benite
Institut Paoli-Calmettes
Hematology, 232 Boulevard De Sainte Marguerite, Bp 156, Marseille

Germany

7 sites · Ongoing, recruiting
Klinikum rechts der Isar der TU Muenchen AöR
N/AKlinik und Poliklinik für Innere Medizin III, Ismaninger Strasse 22, Au-Haidhausen, Munich
Universitat Heidelberg
III. Medizinische Klinik , Hämatologie und Internistische Onkologie, Theodor-Kutzer-Ufer 1-3, Wohlgelegen, Mannheim
Universitaetsklinikum Aachen AöR
Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Pauwelsstrasse 30, 52074, Aachen
Charite Universitaetsmedizin Berlin KöR
Medizinische Klinik m. S. Hämatologie und Onkologie und Tumorimmunologie, Augustenburger Platz 1, Wedding, Berlin
Goethe University Frankfurt
Medizinische Klinik II Hämatologie/Onkologie Studienzentrale, Theodor-Stern-Kai 7, 60590, Frankfurt Am Main
Medizinische Hochschule Hannover
Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Carl-Neuberg-Strasse 1, Gross Buchholz, Hanover
Universitaetsklinikum Jena KöR
Klinik für Innere Medizin II Abt. Hämatologie / Onkologie, Am Klinikum 1, Lobeda, Jena

Italy

3 sites · Ongoing, recruiting
Fondazione IRCCS San Gerardo Dei Tintori
SC Ematologia Adulti, Via Giovanni Battista Pergolesi 33, 20900, Monza
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
SC Ematologia, Via Francesco Sforza 28, 20122, Milan
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Dipartimento di Malattie Oncologiche edEmatologiche, Via Pietro Albertoni 15, 40138, Bologna

Spain

8 sites · Ongoing, recruiting
Hospital Clinic De Barcelona
Hematology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Ramon Y Cajal
Hematology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Quironsalud Zaragoza
Hematology, Paseo Renovales S/n, 50006, Zaragoza
Hospital Universitario 12 De Octubre
Hematology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Universitario De La Princesa
Hematology, Calle De Diego De Leon 62, 28006, Madrid
El Hospital Universitario De Gran Canaria Dr. Negrin
Hematology, Barranco De La Ballena S N, 35010, Las Palmas De Gran Canaria
Institut Catala D'oncologia
Hematology, Carretera Canyet S/n, 08916, Badalona
Hospital Universitari Vall D Hebron
Hematology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-10-28 2024-10-28
Germany 2024-09-11 2024-09-11
Italy 2024-07-17 2024-07-17
Spain 2024-05-17 2024-05-17

Application history

9 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-12-20 Spain Acceptable
2024-04-22
2024-04-22
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-03 Acceptable 2024-07-22
3 SUBSTANTIAL MODIFICATION SM-2 2024-12-17 Spain Acceptable
2025-03-13
2025-03-13
4 SUBSTANTIAL MODIFICATION SM-3 2025-03-25 Acceptable 2025-04-02
5 SUBSTANTIAL MODIFICATION SM-5 2025-03-25 Acceptable 2025-04-18
6 SUBSTANTIAL MODIFICATION SM-4 2025-03-26 Acceptable 2025-04-22
7 SUBSTANTIAL MODIFICATION SM-6 2025-03-27 Spain Acceptable 2025-04-14
8 SUBSTANTIAL MODIFICATION SM-7 2025-06-09 Spain Acceptable
2025-09-05
2025-09-05
9 SUBSTANTIAL MODIFICATION SM-8 2026-02-18 Spain Acceptable
2026-05-25
2026-05-26